Cloaked clot-buster: platelet coating may sharpen attack on arterial blockages

NCT ID NCT07712445

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests a new version of the clot-dissolving drug tenecteplase, coated with platelet membranes, to see if it targets blood clots more effectively. Researchers will apply the coated drug to blood clots made from samples taken from people with coronary artery disease and healthy volunteers. The goal is to measure how well the coated drug dissolves clots compared to the standard drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
platelet membrane-coated tenecteplase (PM-TNK)
What this could lead to
If successful, this could lead to a more targeted clot-dissolving treatment for arterial thrombosis, potentially reducing bleeding risks.
What could go wrong
This is a small, early lab-based study using blood samples, not a full clinical trial in patients. The coated drug may not work better in real-world conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIAL THROMBOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital with Nanjing Medical University

    RECRUITING

    Nanjing, Jiangsu, 210029, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.